Henry Emerle, MD
Psychiatry · Davenport, IANPI 1336450790
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), food and beverage and education — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 60.1% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $2,197, 6.5 times the $336 reported in 2019. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $43.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Neuronetics, Inc.$513
- AbbVie$261
- Teva Pharmaceuticals USA, Inc.$144
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
- Otsuka America Pharmaceutical, Inc.$101
- plus $180 from 9 others
What the payments were for
- Consulting fees$1,84056%
- Food & beverage$1,30740%
- Education$1515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $1,983 |
| Neuronetics, Inc. | 8 | $513 |
| AbbVie(2 entities) | 30 | $261 |
| Teva Pharmaceuticals USA, Inc. | 3 | $144 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Alkermes, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,299 in reported general payments places this provider in the 90th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 60 | $519,680 |
| Austedo XrDeutetrabenazine | 87 | $432,516 |
| Invega SustennaPaliperidone Palmitate | 117 | $396,751 |
| IngrezzaValbenazine Tosylate | 32 | $265,040 |
| AristadaAripiprazole Lauroxil | 41 | $149,905 |
| CaplytaLumateperone Tosylate | 58 | $93,617 |
| LybalviOlanzapine/Samidorphan Malate | 54 | $84,976 |
| Risperdal ConstaRisperidone Microspheres | 36 | $83,472 |
| VraylarCariprazine Hcl | 51 | $66,244 |
| FanaptIloperidone | 27 | $59,339 |
| TrintellixVortioxetine Hydrobromide | 95 | $59,113 |
| Fluphenazine Hcl | 157 | $52,491 |
| QuviviqDaridorexant Hcl | 80 | $40,202 |
| BelsomraSuvorexant | 69 | $35,883 |
| SecuadoAsenapine | 22 | $32,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $144 | $952,197147 claims |
| Alkermes, Inc.Aristada, Lybalvi | $30 | $234,88295 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $116 | $93,61758 claims |
| AbbVieVraylar, Fetzima | $261 | $90,92786 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $18 | $67,866117 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $35 | $40,20280 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $101 | $31,38621 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $5,732577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Davenport
- Anish ReddyDavenport$774
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
- Dwight SchroederCedar Rapids$13K
- Rodney DeanSioux City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.